

**13th AACR-JCA Joint Conference:  
From Cancer Discovery Science to Therapeutic Innovation  
February 1-5, 2025, Hyatt Regency Maui, Maui, HI**

## **CONFERENCE PROGRAM**

### **Saturday, February 1, 2025**

#### **Registration**

**3-7 p.m. | Grand Promenade**

#### **Welcome and Keynotes**

**6-7:30 p.m. | Monarchy 1-4**

- **6:00 p.m. | Welcome and Introduction of Keynote speakers**
- **6:05 p.m. | Cancer trajectory in damaged tissues**  
Hiroyuki Mano, National Cancer Center, Tokyo, Japan
- **6:50 p.m. | Personalized cancer vaccines: Updates and encouraging results**  
Catherine J. Wu, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

#### **Opening Reception**

**7:30-9 p.m. | Halona Kai**

## Sunday, February 2, 2025

### Continental Breakfast and "Networking Roundtables"

7-8 a.m. | Sunset Terrace

### Plenary Session 1: Advances in Cancer Genomics

8-9:30 a.m. | Monarchy 1-4

**Session Chair:** Hiromichi Suzuki, National Cancer Center Japan, Kyoto, Japan

- **8 a.m. | Title to be announced [Virtual presentation]**  
Andrew Futreal, The University of Texas MD Anderson Cancer Center, Houston, Texas
- **8:25 a.m. | Elucidating the pathogenesis of medulloblastoma through the discovery of novel genetic alterations**  
Hiromichi Suzuki
- **8:50 a.m. | New functional genomics methods elucidate the cancer-specific transcriptome**  
Yasuhiro Murakawa, Kyoto University, Kyoto, Japan
- **9:15 a.m. | Anatomical genomic and transcriptomic analyses of Helicobacter pylori-driven gastric transformation\***  
Yosuke Tanaka, National Cancer Center Research Institute, Tokyo, Japan

### Break

9:30-10 a.m. | Grand Promenade

### Plenary Session 2: Cancer Immune Interaction

10-11:30 a.m. | Monarchy 1-4

**Session Chairs:** Hiroyoshi Nishikawa, National Cancer Center, Tokyo, Japan, and Livnat Jerby, Stanford University, Stanford, California, USA

- **10 a.m. | Immuno-genomic cancer evolution governs immune landscapes in the tumor microenvironment**  
Hiroyoshi Nishikawa
- **10:25 a.m. | Title to be announced**  
Elham Azizi, Columbia University, New York, New York, USA
- **10:50 a.m. | Toward new mechanisms to unleash targeted immune responses**  
Livnat Jerby
- **11:15 a.m. | Spatial transcriptome profiling of multicellular dynamics in metastatic gastric cancers: Efficiency of immunotherapy plus vascular endothelial growth factor receptor 2 (VEGFR2) inhibition\***  
Minae An, Samsung Medical Center, Seoul, South Korea

## **Free Time**

**11:30 a.m.-4 p.m.**

## **Plenary Session 3: Cancer Evolution and the Tumor Microenvironment**

**4-5:30 p.m. | Monarchy 1-4**

**Session Chairs:** Nobuyuki Kakiuchi, Kyoto University, Kyoto, Japan, and Sheila A. Stewart, Washington University in St. Louis, St. Louis, Missouri, USA

- **4 p.m. | Somatic mosaicism in non-cancer digestive epithelium**  
Nobuyuki Kakiuchi
- **4:25 p.m. | Title to be announced**  
Sheila A. Stewart
- **4:50 p.m. | Distinct tumor microenvironment phenotypes driven by cancer genotype in gastrointestinal cancer: Insights from mouse models and multi-omics analysis**  
Yoku Hayakawa, The University of Tokyo, Tokyo, Japan
- **5:15 p.m. | Multimodal spatial profiling reveals immune suppression and microenvironment remodeling in fallopian tube precursors to high-grade serous ovarian carcinoma\***  
Tanjina Kader, Harvard Medical School, Boston, Massachusetts, USA

## **Poster Session A**

**5:30-7:30 p.m. | Monarchy 5-7**

## Monday, February 3, 2025

### Continental Breakfast and “Networking Roundtables”

7-8 a.m. | Sunset Terrace

### Plenary Session 4: Genome Instability

8-9:30 a.m. | Monarchy 1-4

**Session Chairs:** Ashok Venkitaraman, Cancer Science Institute of Singapore, Singapore, and Ivana Bozic, University of Washington, Seattle, Washington, USA

- **8 a.m. | Title to be announced**  
Ashok Venkitaraman
- **8:25 a.m. | Title to be announced**  
Ivana Bozic
- **8:50 a.m. | Dissecting the DNA damage response network**  
Alberto Ciccia, Columbia University, New York, New York, USA
- **9:15 a.m. | Advancing precision medicine in pediatric sarcoma: Exploiting DNA damage response pathway for targeted therapies\***  
Larissa Volken, Children's Cancer Institute Australia, Sydney, Australia

### Break

9:30-10 a.m. | Grand Promenade

### Plenary Session 5: Cancer Plasticity and Resistance

10-11:30 a.m. | Monarchy 1-4

**Session Chairs:** Laura D. Attardi, Stanford University, Stanford, California, USA, and Noriko Gotoh, Kanazawa University, Kanazawa, Japan

- **10 a.m. | Illuminating how p53 governs cell state transitions and restricts plasticity in cancer**  
Laura D. Attardi
- **10:25 a.m. | Heterogeneous dormant breast cancer cells leverage bone marrow cell plasticity at the single-cell level to drive metastasis initiation**  
Noriko Gotoh
- **10:50 a.m. | Title to be announced**  
Tuomas Tammela, Memorial Sloan Kettering Cancer Center, New York, New York, USA
- **11:15 a.m. | Systematic interrogation of cancer cell states as drivers of environmental tolerance and therapy resistance in cancer\***  
Srivatsan Raghavan, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

## **Free Time**

**11:30 a.m.-4 p.m.**

## **Plenary Session 6: New Treatment Modalities**

**4-5:30 p.m. | Monarchy 1-4**

**Session Chairs:** Nathaneal S. Gray, Stanford University, Stanford, California, USA, and Mika Kamata-Sakurai, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan

- **4 p.m. | Reprogramming transcription with molecular glues**  
Nathaneal S. Gray
- **4:25 p.m. | Epitope editing enables novel immunotherapies for acute myeloid leukemia**  
Pietro Genovese, Dana-Farber Cancer Institute, Massachusetts, USA
- **4:50 p.m. | Novel approaches in tumor-specific immunotherapy: Targeting immunosuppressive factors in the tumor microenvironment**  
Mika Kamata-Sakurai
- **5:15 p.m. | CRISPR/Cas9 knockout screen identifies SEMA3F gene for resistance to cyclin-dependent kinase 4 and 6 inhibitors in breast cancer\***  
Yuko Kawai, Keio University School of Medicine, Tokyo, Japan

## **Poster Session B**

**5:30-7:30 p.m. | Monarchy 5-7**

**Tuesday, February 4, 2025**

**Continental Breakfast**

**7-8 a.m. | Sunset Terrace**

**Plenary Session 7: Cancer Metabolism**

**8-9:30 a.m. | Monarchy 1-4**

**Session Chairs:** Marcia C. Haigis, Harvard Medical School, Boston, Massachusetts, USA, and Kenji Chamoto, Kyoto University, Kyoto, Japan

- **8 a.m. | Title to be announced**  
Marcia C. Haigis
- **8:25 a.m. | Fatty acid oxidation prevents active aldehyde accumulation and metabolic exhaustion in CD8+ T cells in tumor microenvironment**  
Kenji Chamoto
- **8:50 a.m. | Metabolic reprogramming: A bridge between aging and cancer**  
Ana P. Da Silva Gomes, H. Lee Moffitt Cancer Center, Tampa, Florida, USA
- **9:15 a.m. | Novel aneuploidy-associated therapeutic targets for squamous cell carcinoma\***  
Nadja Zhakula-Kostadinova, Columbia University, New York, New York, USA

**Break**

**9:30-10 a.m. | Grand Promenade**

**Plenary Session 8: Population Sciences**

**10-11:30 a.m. | Monarchy 1-4**

**Session Chairs:** Elizabeth A. Platz, Johns Hopkins University, Baltimore, Maryland, USA, and Tomotaka Ugai, Harvard Medical School, Boston, Massachusetts, USA

- **10 a.m. | Molecular epidemiology studies of cancer risk, early detection, and prognosis**  
Elizabeth A. Platz
- **10:30 a.m. | Integrative cancer population sciences to decipher the etiology of early-onset colorectal cancer**  
Tomotaka Ugai
- **11 a.m. | Bridging mechanisms and prevention: Insights from interactions**  
Keitaro Matsuo, Aichi Cancer Center, Aichi, Japan

## Free Time

**11:30 a.m.-4 p.m.**

## Plenary Session 9: Novel Clinical Trials Platforms

**4-5:30 p.m. | Monarchy 1-4**

**Session Chairs:** Naoto T. Ueno, University of Hawaii Cancer Center, Honolulu, Hawaii, USA, and Takashi Owa, Eisai Inc., Nutley, New Jersey, USA

- **4 p.m. | Repurposing JNK inhibitors: A new path to target cancer through modulation of the tumor microenvironment**  
Naoto T. Ueno
- **4:25 p.m. | Combined inhibition of MEK and HDACs improves the cytotoxicity of CD4 and CD8 T cells in NRAS;ASXL1-driven acute myeloid leukemia mice\***  
Jing Zhang, University of Wisconsin - Madison, Madison, Wisconsin, USA
- **4:40 p.m. | Title to be announced**  
Takashi Owa
- **5:05 p.m. | DXd ADCs, emerging anti-cancer therapeutics with potent efficacy and manageable safety**  
Naoya Harada, Daiichi Sankyo, Tokyo, Japan

## Poster Session C

**5:30-7:30 p.m. | Monarchy 5-7**

## Wednesday, February 5, 2025

### Continental Breakfast

7-8 a.m. | Sunset Terrace

### Plenary Session 10: Novel Roles of RNA in Cancer

8-9:30 a.m. | Monarchy 1-4

**Session Chairs:** Akiko Takahashi, Japanese Foundation for Cancer Research, Tokyo, Japan, and Adrian R. Krainer, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, USA

- **8 a.m. | Targeting epigenetic aberrations in the cancer microenvironment**  
Akiko Takahashi
- **8:25 a.m. | Harnessing mRNA splicing and stability for cancer treatment**  
Akihide Yoshimi, National Cancer Center Japan, Tokyo, Japan
- **8:50 a.m. | Title to be announced**  
Adrian R. Krainer
- **9:15 a.m. | PMR-116, a second generation RNA polymerase I inhibitor\***  
Luc Furic, Peter MacCallum Cancer Centre, Melbourne, Australia

### Break

9:30-10 a.m. | Grand Promenade

### Plenary Session 11: Data Science

10-11:30 a.m. | Monarchy 1-4

**Session Chairs:** Benjamin Haibe-Kains, University of Toronto, Toronto, Ontario, Canada, and Shumpei Ishikawa, University of Tokyo, Tokyo, Japan

- **10 a.m. | The surprisingly complex data science journey of clinical trial matching**  
Benjamin Haibe-Kains
- **10:25 a.m. | Title to be announced**  
Jorge S. Reis-Filho, AstraZeneca, Gaithersburg, Maryland, USA
- **10:50 a.m. | Title to be announced**  
Shumpei Ishikawa
- **11:15 a.m. | Estimating divergence times of founder mutations in cancer predisposition genes in the Japanese population using shared haplotype regions\***  
Wataru Nakamura, National Cancer Center Research Institute, Tokyo, Japan



## **Free Time**

**11:30 a.m.-4 p.m.**

## **Plenary Session 12: Novel Immunotherapies**

**4-5:30 p.m. | Monarchy 1-4**

**Session Chairs:** Aude G. Chapuis, Fred Hutchinson Cancer Center, Seattle, Washington, USA, and Yuki Kagoya, Keio University School of Medicine, Tokyo, Japan

- **4 p.m. | Title to be announced**  
Aude G. Chapuis
- **4:25 p.m. | Understanding T-cell and tumor cell molecular mechanisms of CAR T-cell therapy failure**  
Yuki Kagoya
- **4:50 p.m. | Title to be announced**  
Todd A. Fehniger, Washington University in St. Louis, St. Louis, Missouri, USA
- **5:15 p.m. | KROS 101: A next-generation GITR agonist boosting anti-tumor T cell responses and reprogramming the tumor microenvironment\***  
Tsfahun Admasu, Cedars Sinai Medical Center, Los Angeles, California, USA

## **Poster Session D**

**5:30-7:30 p.m. | Monarchy 5-7**

\*Short talk from proffered abstract